Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
24 USD | +0.33% | +3.90% | +204.18% |
May. 20 | Transcript : Jasper Therapeutics, Inc. - Special Call | |
May. 13 | Jasper Therapeutics to Expand Mast Cell Portfolio, Initiates Asthma Study in Q4 | MT |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | 5.5M | Capitalization | 361M |
---|---|---|---|---|---|
Net income 2024 * | -65M | Net income 2025 * | -78M | EV / Sales 2024 * | - |
Net cash position 2024 * | 217M | Net cash position 2025 * | - | EV / Sales 2025 * | 65.6 x |
P/E ratio 2024 * |
-5.27
x | P/E ratio 2025 * |
-5.85
x | Employees | 45 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 93.39% |
Latest transcript on Jasper Therapeutics, Inc.
1 day | +0.42% | ||
1 week | +2.97% | ||
Current month | +0.21% | ||
1 month | +17.25% | ||
3 months | +13.74% | ||
6 months | +267.60% | ||
Current year | +203.17% |
Managers | Title | Age | Since |
---|---|---|---|
Ronald Martell
CEO | Chief Executive Officer | 62 | 22-03-14 |
Herbert Cross
DFI | Director of Finance/CFO | 52 | 23-09-21 |
Luca Di Noto
CTO | Chief Tech/Sci/R&D Officer | - | 19-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Ronald Martell
CEO | Chief Executive Officer | 62 | 22-03-14 |
Thomas Wiggans
CHM | Chairman | 72 | Oct. 31 |
Kurt von Emster
BRD | Director/Board Member | 56 | 21-09-23 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-28 | 24 | +0.33% | 119 162 |
24-05-24 | 23.92 | +0.42% | 143,905 |
24-05-23 | 23.82 | 0.00% | 186,483 |
24-05-22 | 23.82 | +3.12% | 93,709 |
24-05-21 | 23.1 | -0.56% | 109,083 |
Delayed Quote Nasdaq, May 24, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+203.17% | 361M | |
+38.51% | 727B | |
+32.13% | 594B | |
-6.23% | 354B | |
+18.78% | 328B | |
+1.35% | 277B | |
+14.68% | 243B | |
+8.13% | 205B | |
-5.64% | 203B | |
+6.19% | 164B |
- Stock Market
- Equities
- JSPR Stock